Streetbeat News

DICE

DICE Therapeutics Inc

Industry

Medicinal and Botanical Manufacturing

Open

47.59

Mkt cap

2.3B

Volume

4.3M

High

47.83

P/E Ratio

-21.91

52-wk high

47.90

Low

47.46

Div yield

N/A

52-wk low

15.08

Nine analysts have provided ratings for DICE Therapeutics (NASDAQ:DICE) in the last quarter, with two being bullish and seven indifferent. The average price target is $50.78, which is higher than the current price of $47.55. This average represents a 14.66% decrease from the previous average price target of $59.50.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 8:00 pm

The article lists the top 5 overbought health care stocks that may crash in Q3. These include TC Biopharm (TCBP), Biodesix (BDSX), Revolution Medicines (RVMD), Frequency Therapeutics (FREQ), and DICE Therapeutics (DICE). The companies are considered overbought as their Relative Strength Index (RSI) values are above 70, indicating they may be overvalued.

Portfolio Pulse from Lisa Levin

August 07, 2023 | 12:15 pm

MoonLake Immunotherapeutics (NASDAQ:MLTX) is reportedly seeking a potential sale and has engaged an investment bank for the process. The company, which focuses on antibody-derived treatments for inflammatory skin conditions, is in preliminary talks with interested pharmaceutical companies. MoonLake recently raised $400 million through a stock sale to fund the development of sonelokimab. Since its public debut in 2022, MoonLake's stock price has increased fivefold.

Portfolio Pulse from Vandana Singh

July 17, 2023 | 12:38 pm

Needham analyst Serge Belanger has downgraded DICE Therapeutics (NASDAQ:DICE) from Buy to Hold.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 8:22 am

Canaccord Genuity analyst Edward Nash downgrades DICE Therapeutics (NASDAQ:DICE) from Buy to Hold and lowers the price target from $71 to $48.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 1:23 pm

HC Wainwright & Co. analyst Emily Bodnar downgraded DICE Therapeutics (NASDAQ:DICE) from Buy to Neutral and set a $48 price target.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 10:33 am

Over the past 3 months, 7 analysts have published their opinion on DICE Therapeutics (NASDAQ:DICE) stock, with 3 bullish and 4 indifferent ratings. The average 12-month price target is $52.71, a 5.32% decrease from the previous average of $55.67.

Portfolio Pulse from Benzinga Insights

June 20, 2023 | 8:02 pm

Crude oil prices fell 2%, causing energy shares to dip by 2.4%. Dow Jones dropped over 150 points, NASDAQ fell 0.16%, and S&P 500 dropped 0.33%. Housing starts in the US surged 21.7% month-over-month in May. DICE Therapeutics shares rose 37% after Eli Lilly agreed to acquire the company, while Dragonfly Energy shares plunged 45% after pricing 10 million shares at $2 per share.

Portfolio Pulse from Lisa Levin

June 20, 2023 | 6:36 pm

Health care stocks experienced significant movement during Tuesday's intraday session, with Evelo Biosciences, DICE Therapeutics, Owlet, Zura Bio, Summit Therapeutics, and Biofrontera among the gainers, while Surgalign Holdings, Brainstorm Cell, Gracell Biotechnologies, XTL Biopharmaceuticals, HUTCHMED (China), and Bionomics were among the losers.

Portfolio Pulse from Benzinga Insights

June 20, 2023 | 5:38 pm

Portfolio Pulse from Charles Gross

June 20, 2023 | 5:25 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.